A controlled evaluation of cross-setting medication reconciliation, repeat oversupply prevention and evidence-backed medicines resource opportunities.
Confirm sites, sponsors, data flows, safety case, IG and intervention boundaries.
Observe discrepancies, oversupply signals, pathway resource use and current workload.
Run approved human-reviewed workflows in a limited cohort.
Compare outcomes, workload, safety and verified resource effects.
End with a pre-agreed commissioning decision.
Track selected medication changes from the authorising service through downstream GP, pharmacy and care workflows until reconciliation is confirmed.
Primary measures: unresolved discrepancy rate, time-to-close, downstream acknowledgement, repeat-list correction, obsolete supply prevented and safety events.
Identify selected repeat items where cumulative supply, stock or medication changes suggest another dispensing may not be required.
Primary measures: review yield, items not supplied, intervention workload, patient impact, cost avoidance and missed-essential-medicine safeguards.
Prioritise a small number of evidence-backed route, formulation, preparation or capacity opportunities for local measurement.
Primary measures: pharmacy/nursing minutes, chair or bed time, preparation activity, cancellations, patient outcomes and reusable capacity.
The first live-data phase should detect and record opportunities without changing clinical workflow. Only after data quality, false positives and safety hazards are understood should approved interventions be enabled.
No autonomous stopping, prescribing changes or silent record overwrite. Conflicts are surfaced with provenance and routed to the accountable professional or service for reconciliation.
At week 20 the partner receives the observed baseline, intervention outcomes, safety and workload results, verified benefit classification and a Scale / Modify / Stop recommendation.